Selected article for: "acute respiratory and local site"
Author: Annabi, E.; Dupin, N.; Sohier, P.; Garel, B.; Franck, N.; Aractingi, S.; Guégan, S.; Oulès, B.
Title: Rare cutaneous adverse effects of COVID‐19 vaccines: a case series and review of the literature
  • Cord-id: dq6ztt51
  • Document date: 2021_9_2
    • ID: dq6ztt51
    Snippet: Among the vaccines against coronavirus disease 2019 (COVID-19), BNT162b2 from BioNtech-Pfizer and mRNA-1273 from Moderna are mRNA vaccines targeting the Spike protein of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). The ChAdOx1 nCoV-19 (AZD1222) from Oxford-AstraZeneca is based on adenovirus expressing the full-length Spike protein. Clinical trials reported different cutaneous adverse events, mainly local injection site reactions, either immediate or delayed on/after 8 days.
    Document: Among the vaccines against coronavirus disease 2019 (COVID-19), BNT162b2 from BioNtech-Pfizer and mRNA-1273 from Moderna are mRNA vaccines targeting the Spike protein of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). The ChAdOx1 nCoV-19 (AZD1222) from Oxford-AstraZeneca is based on adenovirus expressing the full-length Spike protein. Clinical trials reported different cutaneous adverse events, mainly local injection site reactions, either immediate or delayed on/after 8 days.

    Search related documents:
    Co phrase search for related documents
    • Try single phrases listed below for: 1